We didn’t start with a business plan. We started with a problem.
The team behind Catalyst spent years as customers. We tried peptides. We saw results. And then we saw the invoice. Six hundred dollars a month. Not for the compound itself, but for the access to it. The knowledge about how to use it. The consistency of supply.
We got priced out. So we built the alternative we needed.
The peptide market isn’t broken because the science is bad. It’s broken because it’s gatekept. Supply is inconsistent. Pricing varies wildly. And there’s a knowledge gap—most people taking these compounds don’t understand what they’re taking or how they work. They’re following a protocol from someone else, without context.
This creates a cycle: access appears, results follow, and then the door closes. Not because the science changed. Because someone decided that scarcity was more profitable than scale.
Access appears, results follow, and then the door closes. Not because the science changed.